Volume 16, Issue 5 (September & October 2025)
BCN 2025, 16(5): 941-948 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
El Otmani H, Daghi M, Abdallaoui M, El Moutawakil B, Rafai M A, Tahiri Jouti N, et al . Subthalamic Nucleus Deep Brain Stimulation in Early-onset Parkinson’s Disease: Clinical Outcomes in LRRK2 Mutation Carriers Compared to Non-Carriers. BCN 2025; 16 (5) :941-948
URL: http://bcn.iums.ac.ir/article-1-3182-en.html
URL: http://bcn.iums.ac.ir/article-1-3182-en.html
Hicham El Otmani *1 
, Mohamed Daghi2 , Maha Abdallaoui3 , Bouchra El Moutawakil4 , Mohammed Abdoh Rafai5 , Nadia Tahiri Jouti6 , Suzanne Lesage7 , Abdelhakim Lakhdar8
, Mohamed Daghi2 , Maha Abdallaoui3 , Bouchra El Moutawakil4 , Mohammed Abdoh Rafai5 , Nadia Tahiri Jouti6 , Suzanne Lesage7 , Abdelhakim Lakhdar8
1- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco. & Laboratory of Cellular and Molecular Inflammatory, Degenerative and Oncologic Pathophysiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco. & Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
2- Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
3- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco.
4- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco. & Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
5- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco. & Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
6- Laboratory of Cellular and Molecular Inflammatory, Degenerative and Oncologic Pathophysiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
7- Institut du Cerveau, Institut du Cerveau, Institut National de la Santé et de la Recherche Médicale, and Centre National de la Recherche Scientifique, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France.
8- Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco. & Department of Neurosurgery, Ibn Rochd University Hospital Center, Casablanca, Morocco.
2- Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
3- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco.
4- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco. & Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
5- Department of Neurology, Ibn Rochd University Hospital Center, Casablanca, Morocco. & Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
6- Laboratory of Cellular and Molecular Inflammatory, Degenerative and Oncologic Pathophysiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
7- Institut du Cerveau, Institut du Cerveau, Institut National de la Santé et de la Recherche Médicale, and Centre National de la Recherche Scientifique, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France.
8- Research Laboratory of Nervous System Diseases, Neurosensory Disorders, and Disability, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco. & Department of Neurosurgery, Ibn Rochd University Hospital Center, Casablanca, Morocco.
Abstract:
Introduction: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for early-onset Parkinson’s disease (EOPD). While the effect of STN-DBS on patients with LRRK2 G2019S mutation has been largely investigated, data specific to EOPD patients with this mutation remain scarce. This study examines the impact of the LRRK2 G2019S mutation on STN-DBS outcomes in EOPD patients in Morocco, a developing country where such treatment is challenging to provide.
Methods: A prospective cohort study was conducted at the University Hospital of Ibn Rochd in Casablanca. Genomic DNA was analyzed for the LRRK2 G2019S mutation, and clinical data were collected before and after surgery. Motor outcomes, including dyskinesia, motor fluctuations, and reduction in levodopa equivalent daily dose (LEDD), were assessed one year post-DBS.
Results: Seventeen EOPD patients who underwent STN-DBS were included, with 10(58.8%) being carriers of the LRRK2 G2019S mutation. The mean age of participants was 57.2±8.4 years, with a mean age at onset of 37.9±6.2 years. Motor fluctuations were present in 88.2% of patients, and 94.1% experienced dyskinesia. Following DBS, both mutation carriers and non-carriers demonstrated significant improvements in motor symptoms, with a mean improvement of 61.3% in the unified PD rating scale (UPDRS) III. Dyskinesia and motor fluctuations, as measured by specific UPDRS IV items, improved by 77.1% and 83.8%, respectively, with a mean LEDD reduction of 60.6%. Improvements were comparable between LRRK2 G2019S carriers and non-carriers. All patients were satisfied with the treatment, though one patient had a hardware-related infection.
Conclusion: STN-DBS is effective in managing motor symptoms and reducing medication needs in EOPD patients, regardless of LRRK2 G2019S mutation status.
Methods: A prospective cohort study was conducted at the University Hospital of Ibn Rochd in Casablanca. Genomic DNA was analyzed for the LRRK2 G2019S mutation, and clinical data were collected before and after surgery. Motor outcomes, including dyskinesia, motor fluctuations, and reduction in levodopa equivalent daily dose (LEDD), were assessed one year post-DBS.
Results: Seventeen EOPD patients who underwent STN-DBS were included, with 10(58.8%) being carriers of the LRRK2 G2019S mutation. The mean age of participants was 57.2±8.4 years, with a mean age at onset of 37.9±6.2 years. Motor fluctuations were present in 88.2% of patients, and 94.1% experienced dyskinesia. Following DBS, both mutation carriers and non-carriers demonstrated significant improvements in motor symptoms, with a mean improvement of 61.3% in the unified PD rating scale (UPDRS) III. Dyskinesia and motor fluctuations, as measured by specific UPDRS IV items, improved by 77.1% and 83.8%, respectively, with a mean LEDD reduction of 60.6%. Improvements were comparable between LRRK2 G2019S carriers and non-carriers. All patients were satisfied with the treatment, though one patient had a hardware-related infection.
Conclusion: STN-DBS is effective in managing motor symptoms and reducing medication needs in EOPD patients, regardless of LRRK2 G2019S mutation status.
Keywords: Early-onset Parkinson’s disease (EOPD), Deep-brain stimulation, Subthalamic nucleus, LRRK2 mutations
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2025/04/2 | Accepted: 2025/06/24 | Published: 2025/09/1
Received: 2025/04/2 | Accepted: 2025/06/24 | Published: 2025/09/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
